AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Juvaris BioTherapeutics, Inc., announced that researchers at the University of New Mexico have begun evaluating the efficacy of the JuvImmune immunostimulant platform against anthrax and small pox infection models.
This novel technology is capable of rapidly activating the innate immune response for the production of different cytokines including interferons (alpha, beta, and gamma) as well as IL-12 and TNF-alpha.
These cytokines are the first-line of defense against infectious agents and are critical for induction of subsequent immune responses. Preclinical results from rodent, canine and non-human primate studies have demonstrated substantial amplification of immune responses by the JuvImmune immunostimulant.
In addition, the testing will determine the efficacy of the JuvaVax vaccine platform containing disease-specific antigens as a potential oral vaccine against anthrax.
JuvaVax vaccines have demonstrated significant induction of both humoral (antibody) and cellular (cytotoxic T lymphocytes) antigen-specific immune responses.
These balanced immune responses are essential for preventing ...